Cancer immune evasion can also be achieved through the binding of programmed death ligand-1 (PD-L1) or -2 (PD-L2) on the cancer cells to programmed cell death protein-1 (PD-1) on the surface of T cells, which inhibits T cell activation by inducing T cell exhaustion [35,36]. This evidence concerns the gene PDCD1 and cancer.